Cholera

10
Pipeline Programs
5
Companies
7
Clinical Trials
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
4
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 6 programs with unclassified modality

On Market (4)

Approved therapies currently available

Bayer
CIPROApproved
ciprofloxacin
Bayer
injection1990
Bayer
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINERApproved
ciprofloxacin
Bayer
injection1990
U
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINERApproved
ciprofloxacin
Unknown Company
Fluoroquinolone Antibacterial [EPC]injection2008
U
OTIPRIOApproved
ciprofloxacin
Unknown Company
otic2015

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
1
1
CiprofloxacinPhase 3Small Molecule1 trial
Active Trials
NCT00142272Completed180Est. Jul 2002
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
4 programs
1
3
PXVX0200Phase 31 trial
PXVX0200Phase 31 trial
PXVX0200 Lot APhase 31 trial
PXVX0200Phase 11 trial
Active Trials
NCT01585181Completed66Est. Jan 2013
NCT01895855Completed197Est. Nov 2014
NCT02100631Completed398Est. Jun 2015
+1 more trials
Pharmaron
PharmaronRI - Coventry
1 program
1
iOWH032Phase 21 trial
Active Trials
NCT04150250CompletedEst. Jul 2020
Alliance Pharmaceuticals
1 program
ShancholN/A1 trial
Active Trials
NCT02727855Completed75,170Est. Oct 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bavarian NordicPXVX0200
Bavarian NordicPXVX0200 Lot A
Bavarian NordicPXVX0200
BayerCiprofloxacin
PharmaroniOWH032
Bavarian NordicPXVX0200
Alliance PharmaceuticalsShanchol

Clinical Trials (7)

Total enrollment: 79,157 patients across 7 trials

NCT02100631Bavarian NordicPXVX0200

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

Start: May 2014Est. completion: Jun 2015398 patients
Phase 3Completed
NCT02094586Bavarian NordicPXVX0200 Lot A

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Start: May 2014Est. completion: Jun 20153,146 patients
Phase 3Completed
NCT01895855Bavarian NordicPXVX0200

Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera

Start: Sep 2013Est. completion: Nov 2014197 patients
Phase 3Completed
NCT00142272BayerCiprofloxacin

Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial

Start: May 2001Est. completion: Jul 2002180 patients
Phase 3Completed
NCT04150250PharmaroniOWH032

Cholera Anti-Secretory Treatment Trial

Start: Nov 2019Est. completion: Jul 2020
Phase 2Completed
NCT01585181Bavarian NordicPXVX0200

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

Start: Apr 2012Est. completion: Jan 201366 patients
Phase 1Completed
NCT02727855Alliance PharmaceuticalsShanchol

Cholera Vaccine Investment Strategy in Bangladesh

Start: Jan 2016Est. completion: Oct 201975,170 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space